🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Xenon Pharmaceuticals Inc. XENE R2K

Healthcare · Biotechnology · Canada
https://www.xenon-pharma.com
Company Profile ↓
$67.30
+106.44% 1Y
Mkt Cap$6.51B
P/E-14.29
P/B8.26
52W High$70.96
52W Low$30.30
Book Value$7.27
EPS (TTM)$-4.71

Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Recent Developments

  • 5-Year Trend Long-term compounding — revenue CAGR -7.4%, profit CAGR -58.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-7.36%
1 Year:-

Compounded Profit Growth

5 Years:-58.63%
1 Year:-

Stock Price Performance

1 Year:+106.44%
6 Months:+59.67%
3 Months:+14.85%
1 Month:+28.95%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 91% of range
$30.30 $70.96
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)70.42 · Overbought
Price Performance
1M+28.95%
3M+14.85%
6M+59.67%
1Y+106.44%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -7.4% CAGR over 5 years.
  • Earnings shrank at -58.6% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-14.29
Industry PE
25.41
Forward P/E
-13.43
PEG Ratio
-
Book Value
$7.27
Price to Book
8.26
P/S
inf
EV/EBITDA
-11.71
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-7.36%
Profit 5Y
-58.63%
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-63.09%
ROE
-37.53%
ROA
-24.22%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-1.17
EPS (TTM)
$-4.71

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
27.52
Current Ratio
27.79
Debt
$7.49M
Total Assets
$1.39B
Current Assets
$1.11B
Working Capital
$518.86M

Ownership

Promoter Holding
0.12%
Chg in Prom Hold
-0.00%
FII / Inst Holding
107.29%
Chg in FII Hold
-3.79%

Financial Snapshot

Enterprise Value
$6.51B
Total Revenue (TTM)
$0
EBITDA
$-410.19M
Free Cash Flow
$-186.27M
Operating Cash Flow
$-306.36M
Shares Outstanding
96.67M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 XENE Xenon Pharmaceuticals Inc. R2K 67.30 -14.29 $6.51B 0.00% -63.09% -37.53% -7.36% -58.63%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------264.00K----------------------7.50M0000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------80.24M94.23M96.34M109.77M112.33M
Operating Income 8.66M35.00K-6.14M199.00K-820.00K-2.60M-5.66M-6.37M-7.33M-5.46M-7.99M-7.89M-8.64M-8.05M-7.81M-7.59M-14.19M-11.76M-10.51M-8.95M-8.03M-646.00K-9.70M-16.06M-22.50M-15.60M-17.37M-30.32M-38.13M-49.05M-55.62M-55.68M-59.04M-69.10M-73.68M-72.74M-94.23M-96.34M-109.77M-112.33M
EBITDA ------------------------------------72.08M-93.60M-95.69M-109.16M-111.74M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------64.62M-85.33M-90.22M-104.72M-104.87M
Tax Provision -----------------------------------427.00K-626.00K677.00K538.00K-2.57M
Net Income 9.19M--9.16M1.17M-3.83M-3.94M-3.26M-6.02M-7.71M-6.00M-7.52M-7.38M-7.74M-8.06M-3.75M-7.80M-14.38M-11.34M-10.01M-8.87M-7.48M-175.00K-8.86M-15.76M-22.11M-15.45M-19.67M-31.16M-37.15M-41.73M-47.46M-48.46M-47.93M-57.92M-62.79M-65.05M-84.71M-90.90M-105.26M-102.30M
Diluted EPS 1.690.13-0.64-0.07-0.27-0.27-0.23-0.42-0.51--0.43-0.41-0.43-0.45-0.21-0.45-0.63-0.42-0.37--0.00---0.51-0.36-0.35-0.55-0.57-0.63-0.72-0.73-0.62-0.75-0.81-0.83-1.07-1.15-1.31-1.17
R&D Expense 3.22M-3.43M3.67M3.79M-4.36M5.10M5.96M-5.90M6.11M7.16M-5.57M5.42M6.25M9.14M8.21M9.75M11.79M10.72M13.04M16.31M18.38M18.89M19.36M22.15M29.43M39.52M44.04M42.88M44.25M49.70M56.97M61.20M74.98M77.05M-88.51M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 14.31M27.36M28.37M15.58M1.80M311.00K-6.83M32.17M-9.43M007.50M
Cost of Revenue --------------
Gross Profit --------------
Operating Expenses ----------138.58M214.05M279.30M380.57M
Operating Income -3.15M9.71M11.11M-9.36M-24.82M-32.58M-38.04M-42.82M-31.30M--129.14M-214.05M-279.30M-373.07M
EBITDA -----------127.74M-211.99M-276.74M-370.53M
Interest Expense ---------00---
Pretax Income -----------125.25M-182.69M-238.42M-344.89M
Tax Provision ----------118.00K-292.00K-4.09M1.02M
Net Income -4.30M12.03M13.02M-15.75M-23.00M-30.70M-34.50M-41.59M-28.84M--125.37M-182.39M-234.33M-345.91M
Diluted EPS -3.241.913.28-1.10-1.48-1.72-1.63--0.81--2.06-2.73-3.01-4.36
R&D Expense 10.46M12.30M11.77M15.15M19.83M25.57M23.63M38.84M50.52M75.46M105.77M167.51M210.39M300.94M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --54.49M87.42M63.95M67.49M46.12M122.43M147.70M189.19M-754.15M964.80M798.14M633.16M
Current Assets -----------600.30M644.96M635.26M560.65M
Cash & Equivalents 13.93M60.16M37.95M72.03M58.65M17.09M20.49M67.75M24.75M45.01M-57.24M148.64M142.71M199.16M
Inventory ---------------
Receivables -----------986.00K874.00K1.47M1.37M
Total Liabilities --30.37M14.64M2.92M3.59M10.19M19.13M55.72M17.83M-32.65M36.88M43.24M51.40M
Current Liabilities --18.20M14.29M2.78M3.59M4.08M4.12M43.38M14.78M-22.70M27.27M35.59M41.79M
Long Term Debt ------6.10M15.01M10.89M------
Total Debt -----------10.44M10.90M9.02M7.94M
Total Equity -86.32M-89.86M-78.37M72.78M61.03M63.90M35.93M103.30M91.98M171.35M-721.50M927.92M754.90M581.76M
Shares Outstanding -----------62.59M75.37M76.42M80.01M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------28.73M-34.72M-4.71M-48.12M--101.03M-151.11M-181.39M-279.12M
Investing Cash Flow -----24.29M-28.99M-66.21M-16.82M--293.40M-111.39M165.00M218.00M
Financing Cash Flow -----7.07M111.59M27.52M85.80M-278.47M353.52M12.13M117.11M
Capital Expenditure -526.00K-156.00K-1.53M-551.00K-279.00K-315.00K-507.00K-1.24M-2.64M--2.89M-5.62M-3.08M-799.00K
Free Cash Flow ------29.04M-35.23M-5.95M-50.76M--103.92M-156.73M-184.46M-279.92M
Net Change in Cash -----------115.96M91.03M-4.26M55.99M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------
Operating Margin % -22.0%35.5%39.1%-60.1%-1,376.4%-10,474.3%--627.0%-97.3%--1,368.9%---4,974.3%
Net Margin % -30.1%44.0%45.9%-101.1%-1,275.5%-9,872.7%--609.1%-89.7%--1,328.9%---4,612.1%
ROE % 4.8%-15.4%17.9%-25.8%-36.0%-85.4%-33.4%-45.2%-16.8%--17.4%-19.7%-31.0%-59.5%
ROCE % -26.8%15.2%-15.3%-38.8%-77.5%-32.2%-41.0%-17.9%--17.7%-22.8%-36.6%-63.1%

Shareholding Pattern

Insiders
0.12%
Institutions
107.29%
Public Float
107.42%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 11.19% 10.82M $649.76M
2 Avoro Capital Advisors LLC 5.98% 5.78M $347.01M
3 Blackrock Inc. 5.83% 5.64M $338.75M
4 Wellington Management Group, LLP 5.00% 4.83M $290.07M
5 Driehaus Capital Management, LLC 4.65% 4.49M $269.77M
6 Polar Capital Holdings PLC 4.56% 4.41M $264.58M
7 Janus Henderson Group PLC 4.32% 4.18M $250.81M
8 Capital International Investors 2.77% 2.67M $160.64M
9 Citadel Advisors Llc 2.74% 2.65M $159.34M
10 JPMORGAN CHASE & CO 1.99% 1.92M $115.53M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XENE

Google News ue, 14 Jul 2026

Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds - Sahm

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQX3RCX3NuS1I5bTJFYThHbUtMNmJTN0hzTGNkMnl2Tkhqemc3NUR6ci1kSTFSNzVaNFVyZEVtUzdBV00yQ1lmYkNkZGNOOEZxQU5RN0RBVFRYSE13c1poLXlQNXFwdzNBenNCUkRlT1VzbW1KQS1hZ3BRYXppLUhkNUFqc0pfWVlWM1g2VX…

Google News Mon, 13 Jul 2026

Price to sales forward of Xenon Pharmaceuticals Inc. – BIVA:XENE/N - TradingView

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOakdzenJNbDRsemNSa05WOWxBS2tucHVzZFJodkVzdUJjU2N6dV9QaXZLZU9MQUgzVGk5TjhleGh6cnRYVG9CMTRWSElLTk95eGtzcTQydk9SdEs5YWhmaWVlQ3lENHh3VWNYY3FERHFfWjQwcmhkdGJfWXc3aEQ5QXhKNUkxUEF0MTZINU…

Google News Fri, 10 Jul 2026

Understanding the Setup: (XENE) and Scalable Risk - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOY3EycDZ2SENnRFVoZFo5cEZKZUtxWUdHWjdIc2J5NklhVlZtUTNPQlNEbDhkUk96VzZBa3hiU0I2Tm4yUkJsbjU5ODhaeEtXenViSS1SS19yRGl4SGZBSFJRVXdaZVdvSTFfajNUZ0lhLVFXbGlHd2w3SFhXU1JRMjJUWkNLNWdoeFgzSE…

Google News hu, 02 Jul 2026

Xenon awards new hires 20,200 options and 11,850 RSUs - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVnl1Qk1TRm9ObTlVT1lPdFBTWUU1SWFPVnZia0RILTI2bENaekpTdVFOX0tmRXZPQVZ5dDgzR2pGVlVJV1dSZllsWFg0V1hGaE5DZ0VKNTh6OUdmV3YtT2FvaTFRRHV2aTVlXzV3OHNQaUIwbjNTTXVuLTNOZnF4dEF0Z3FsLUs1eTZPYV…

Google News ue, 10 Mar 2026

XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQWldIT2U3YTUzU3Y2YTJRRnRQWmhDTWxIQ3I0MkpDN3dORGE1eW9WWEpxZW9ZV3FxV3lGVjMxOHp6UzZkUzRxMVJJQnhpdXFsTzgzRXVjc2Q1NjhOWElxUmNaZWF6eDZxR0sxMU1nV2hSaEpoMHlnM2IySlFBZE92aEVBemhmQQ?oc=5" t…

Google News Mon, 09 Mar 2026

Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations | XENE Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTW8zQkt6RXBZcUVNZEc1SVRVUkFxV3FKeVU0eldZVzFJMS1WQ0I1UGJ6a2wzcUFTV05Ubmx5V2d6UlBWQk1UV0tDTzVzVWdWMEZyNlZUWV9ZU0xDcnFhTlJDTWJDeURxVlpFTEFZZHU5MnlCOExFUFZUN2V1eXZDZHEwd00tUGRSU1AyY2…

XENE — Frequently Asked Questions

What is the current share price of Xenon Pharmaceuticals Inc. (XENE)?

As of 2026-07-14 21:23 PDT, Xenon Pharmaceuticals Inc. (XENE) trades at $67.30 on NasdaqGM. Its 52-week range is $30.30 to $70.96.

What is the market capitalisation of XENE?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalisation of $6.51B on NasdaqGM.

What is the P/E ratio of XENE?

XENE trades at a trailing price-to-earnings (P/E) ratio of -14.29. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 8.26.

What is the return on equity (ROE) of XENE?

XENE has a return on equity (ROE) of -37.53%. Its return on capital employed (ROCE) is -63.09%.

Is XENE a good stock to buy?

This page provides a data-driven analysis of Xenon Pharmaceuticals Inc. (XENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space